SRR1446287
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.465
- PANCREAS_BETA_CELLS+0.331
- MYOGENESIS+0.197
- BILE_ACID_METABOLISM+0.189
- SPERMATOGENESIS+0.154
- COAGULATION+0.148
- ESTROGEN_RESPONSE_LATE+0.146
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.117
- XENOBIOTIC_METABOLISM+0.083
- HEDGEHOG_SIGNALING+0.052
Top 10 suppressed
- MYC_TARGETS_V2-0.526
- MYC_TARGETS_V1-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.503
- DNA_REPAIR-0.496
- MTORC1_SIGNALING-0.452
- PROTEIN_SECRETION-0.423
- OXIDATIVE_PHOSPHORYLATION-0.412
- CHOLESTEROL_HOMEOSTASIS-0.387
- PI3K_AKT_MTOR_SIGNALING-0.369
- UV_RESPONSE_UP-0.336
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1336006 | GTEX | — | 0.961 |
| 2 | SRR1451964 | GTEX | — | 0.958 |
| 3 | SRR1472663 | GTEX | — | 0.957 |
| 4 | SRR1360674 | GTEX | — | 0.952 |
| 5 | SRR1500405 | GTEX | — | 0.941 |
| 6 | SRR1360150 | GTEX | — | 0.940 |
| 7 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.940 |
| 8 | BS_0X9EGHY2 | low-grade glioma | — | 0.938 |
| 9 | SRR662091 | GTEX | — | 0.938 |
| 10 | SRR1348861 | GTEX | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.465 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.331 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.197 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.189 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.154 | Inavolisib | — uncovered |
| COAGULATION | 0.148 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.146 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.117 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.083 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.052 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.012 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |